SEC Form 4 · accession 0001144204-15-051521
Celator Pharmaceuticals Inc · CPXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Dougherty
Officer — Executive Chairman · Director
Period of report
Aug 20, 2015
Accepted (ET)
Aug 24, 2015 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001327467
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.18 | Aug 20, 2015 | A | 500,000 | A | — | Aug 20, 2025 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable in 35 consecutive monthly installments of 13,889 shares each on the 20th day of each month beginning September 20, 2015 and continuing through July 20, 2018 and a final installment of 13,885 shares on August 20, 2018. The option will vest in full and become immediately exercisable upon a change of control, as defined in the Celator Pharmaceuticals, Inc. 2013 Equity Incentive Plan, irrespective of whether the option, or any portion thereof, had yet become exercisable.